"10.1371_journal.pone.0039741","plos one","2012-06-27T00:00:00Z","Karen Nieto; Margit Weghofer; Peter Sehr; Mirko Ritter; Sebastian Sedlmeier; Balasubramanyam Karanam; Hanna Seitz; Martin Müller; Markus Kellner; Markus Hörer; Uwe Michaelis; Richard B S Roden; Lutz Gissmann; Jürgen A Kleinschmidt","Research Program Infection and Cancer, German Cancer Research Center, Heidelberg, Germany; MediGene AG, Planegg/Martinsried, Germany; Chemical Biology Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany; Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America","Conceived and designed the experiments: MH JAK MM LG. Performed the experiments: KN PS SS BK RBSR MK MR. Analyzed the data: KN PS MW. Contributed reagents/materials/analysis tools: HS MR MK. Wrote the paper: KN JAK MM MW LG. Organizational support: UM.","The authors have read the journal’s policy and have the following conflicts: MW, MR, SS, MK, MH and UM are or were employees of MediGene AG when the study was performed. MR, SS, MK, MH and UM hold stocks or stock options of MediGene AG. The corresponding author had full access to all the data and had the final editorial rights of the manuscript. MR and MH are inventors to a patent application with the application number PCT/EP2011/004528 entitled “Cross-protective HPV L2 vaccine based on AAVLPs” filed by MediGene AG. RBSR is a co-inventor on L2 patents licensed to Shantha Biotechnics Ltd., GlaxoSmithKline, PaxVax, Inc. and Acambis, Inc. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.","2012","06","Karen Nieto","KN",14,TRUE,4,7,3,5,TRUE,TRUE,FALSE,0,NA,FALSE
